PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Outcomes of iontophoretic corneal collagen crosslinking in keratoconic eyes with very thin corneas.

Abstract The purpose of this retrospective study was to report the results of iontophoretic corneal collagen crosslinking (I-CXL) with riboflavin and ultraviolet A irradiation in patients affected by keratoconus, each with thinnest pachymetry values of <400 μ (with epithelium) and not treatable using standard epithelium-off technique.Fifteen eyes of 15 patients affected by progressive keratoconus and with thinnest pachymetry values <400 μ underwent I-CXL. The uncorrected (UDVA) and corrected (CDVA) distance visual acuity, maximum and minimum keratometry (K max and K min) readings, corneal thickness at the thinnest point (CTTP), endothelial cell density (ECD), and intraocular pressure (IOP) were assessed before I-CXL, at 1, 3, 6, and 12 months postoperatively.The mean UDVA and CDVA significantly increased 12 months after I-CXL (P = .002 for both comparisons). The K max readings significantly decreased at 6 and 12 months postoperatively (P = .04 and P = .02, respectively). The mean CTTP improved at the end of the follow-up (P = .008). ECD was unchanged. No side effects or damage to the limbal region was observed during the follow-up period.I-CXL has been proved to be effective in halting keratoconus progression in eyes with very thin corneas, with no side effects during the follow-up period. This procedure could be used in patients with more advanced keratoconus.
PMID
Related Publications

Factors affecting outcomes of corneal collagen crosslinking treatment.

Standard corneal collagen crosslinking versus transepithelial iontophoresis-assisted corneal crosslinking, 24 months follow-up: randomized control trial.

Corneal collagen cross-linking with riboflavin and ultraviolet-A irradiation in patients with thin corneas.

Outcomes of corneal collagen crosslinking using a customized epithelial debridement technique in keratoconic eyes with thin corneas.

Iontophoretic collagen cross-linking versus epithelium-off collagen cross-linking for early stage of progressive keratoconus - 3 years follow-up study.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29381972
OWN - NLM
STAT- MEDLINE
DCOM- 20180208
LR  - 20180208
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 47
DP  - 2017 Nov
TI  - Outcomes of iontophoretic corneal collagen crosslinking in keratoconic eyes with 
      very thin corneas.
PG  - e8758
LID - 10.1097/MD.0000000000008758 [doi]
AB  - The purpose of this retrospective study was to report the results of
      iontophoretic corneal collagen crosslinking (I-CXL) with riboflavin and
      ultraviolet A irradiation in patients affected by keratoconus, each with thinnest
      pachymetry values of &lt;400 mu (with epithelium) and not treatable using standard
      epithelium-off technique.Fifteen eyes of 15 patients affected by progressive
      keratoconus and with thinnest pachymetry values &lt;400 mu underwent I-CXL. The
      uncorrected (UDVA) and corrected (CDVA) distance visual acuity, maximum and
      minimum keratometry (K max and K min) readings, corneal thickness at the thinnest
      point (CTTP), endothelial cell density (ECD), and intraocular pressure (IOP) were
      assessed before I-CXL, at 1, 3, 6, and 12 months postoperatively.The mean UDVA
      and CDVA significantly increased 12 months after I-CXL (P = .002 for both
      comparisons). The K max readings significantly decreased at 6 and 12 months
      postoperatively (P = .04 and P = .02, respectively). The mean CTTP improved at
      the end of the follow-up (P = .008). ECD was unchanged. No side effects or damage
      to the limbal region was observed during the follow-up period.I-CXL has been
      proved to be effective in halting keratoconus progression in eyes with very thin 
      corneas, with no side effects during the follow-up period. This procedure could
      be used in patients with more advanced keratoconus.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Cantemir, Alina
AU  - Cantemir A
AD  - Grigore T. Popa University of Medicine and Pharmacy.
FAU - Alexa, Anisia-Iuliana
AU  - Alexa AI
AD  - Grigore T. Popa University of Medicine and Pharmacy.
FAU - Galan, Bogdan Gabriel
AU  - Galan BG
AD  - Sanoptic Eye Center, Iasi, Romania.
FAU - Anton, Nicoleta
AU  - Anton N
AD  - Grigore T. Popa University of Medicine and Pharmacy.
FAU - Ciuntu, Roxana Elena
AU  - Ciuntu RE
AD  - Grigore T. Popa University of Medicine and Pharmacy.
FAU - Danielescu, Ciprian
AU  - Danielescu C
AD  - Grigore T. Popa University of Medicine and Pharmacy.
FAU - Chiselita, Dorin
AU  - Chiselita D
AD  - Grigore T. Popa University of Medicine and Pharmacy.
FAU - Costin, Danut
AU  - Costin D
AD  - Grigore T. Popa University of Medicine and Pharmacy.
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Cross-Linking Reagents)
RN  - 0 (Photosensitizing Agents)
RN  - 9007-34-5 (Collagen)
RN  - TLM2976OFR (Riboflavin)
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Collagen/*therapeutic use
MH  - Cornea/pathology
MH  - Cross-Linking Reagents/*therapeutic use
MH  - Female
MH  - Humans
MH  - Iontophoresis/*methods
MH  - Keratoconus/pathology/*therapy
MH  - Male
MH  - Photosensitizing Agents/therapeutic use
MH  - Retrospective Studies
MH  - Riboflavin/therapeutic use
MH  - Treatment Outcome
MH  - Ultraviolet Therapy/*methods
MH  - Young Adult
PMC - PMC5708971
EDAT- 2018/02/01 06:00
MHDA- 2018/02/09 06:00
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/02/09 06:00 [medline]
AID - 10.1097/MD.0000000000008758 [doi]
AID - 00005792-201711270-00063 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Nov;96(47):e8758. doi: 10.1097/MD.0000000000008758.